SC 1-29: Million Person Study Scientific Advisory Committee

is currently a Special Government Employee (Expert) with the Radiation Protection Division of the U.S. Environmental Protection Agency (EPA). He was previously the Associate Director for Health for the National Health and Environmental Effects Research Laboratory of EPA. He also served as Director of the Environmental Carcinogenesis Division at EPA and as senior science adviser at the Chemical Industry Institute of Toxicology. He has been employed at the Biology Division of the Oak Ridge National Laboratory and has served as Associate Director for the Oak Ridge-University of Tennessee Graduate School for Biomedical Sciences. Dr. Preston's research and current activities have focused on the mechanisms of radiation and chemical carcinogenesis and the approaches for incorporating these types of data into cancer risk assessments by integrating epidemiology and radiation biology.

Dr. Preston currently serves on NCRP committees and as a member of the National Academy of Sciences (NAS) Nuclear and Radiation Studies Board. He was recently a member of an Office of Science and Technology Policy Committee on Low Dose Radiation Research. He was also recently co-chair of an NAS Committee for a National Aeronautics and Space Administration sponsored project on revising dose limits for astronauts. Dr. Preston was chair of Committee 1 of the International Commission on Radiological Protection (ICRP), a member of the ICRP Main Commission, and the Representative and a member of the U.S. delegation to the United Nations Scientific Committee on the Effects of Atomic Radiation. He served as Chair for the National Research Council's Committee to Assess the Scientific Information for the Radiation Exposure Screening and Education Program and on the Task Group on the Biological Effects of Space Radiation. He is an associate editor of Environmental and Molecular Mutagenesis. Dr. Preston has had more than 250 peer-reviewed papers and chapters published. He received his BA and MA from Peterhouse, Cambridge University, England, ingenetics and his PhD from Reading University, England, in radiation genetics.

is an Attending Epidemiologist at the Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City. Her core research focus is on breast cancer and gliomas and on understanding cancer risk and progression in order to identify those at highest risk because of gene carrier status, environmental exposures, or a combination of both. Dr. Bernstein is the Principle Investigator of the National Cancer Institute (NCI)-funded international 24-center Women's Environmental Cancer Radiation and Epidemiologic (WECARE) Study which was specifically designed to examine the interaction of radiation exposure and genetic predisposition in breast cancer, especially radiation-associated contralateral breast cancer (CBC) among 3,700 women with CBC and unilateral breast cancer.

The WECARE Study has served as the source population for studies of candidate genes such as BRCA1, BRCA2, CHEK2, and ATM, candidate gene pathways of DNA damage response involved in radiation-induced double-strand break repair—ATM, CHEK2, P53 binding protein (53BPI), and MDC1, Mre11, Rad50, and Nbs1 (e.g., MRN nuclease complex), a genome-wide association study, and most recently mammographic density. The global hypothesis across these studies is that women who carry certain types of mutations will be more susceptible to breast cancer than noncarriers, and possibly to radiation-associated breast cancer. Dr. Bernstein currently serves as a member of the Board of Directors of the American College of Epidemiology, the External Advisory group for the NCI-sponsored Breast Cancer Family Registry, the National Council on Radiation Protection and Measurements, and most recently the NCI Board of Scientific Counselors-Clinical Sciences and Epidemiology.

For the past two years, she has served on the Organizing Committee of the American Statistical Association Conference on Radiation and Health (2012 and 2014 meetings), and was Co-Chair of the Third North American Congress of Epidemiology, held in June 2011 for which she was honored by the 2012 ACE Award for Leadership and Service in Epidemiology. Dr. Bernstein holds a PhD in Epidemiology from Yale University, an MS in Applied Biometry from the University of Southern California, and an AB from Brown University. Before joining the faculty at MSKCC, she was Deputy Director of the Division of Epidemiology at Mount Sinai School of Medicine.

is Professor of Biomedical Engineering and Medical Physics in the J. Crayton Pruitt Family Department of Biomedical Engineering at the University of Florida (UF). He serves as Director of the Advanced Laboratory for Radiation Dosimetry Studies at UF. Dr. Bolch earned his BSE degree in environmental engineering in 1984, his ME and PhD degrees in radiological physics in 1986 and 1998, respectively, from the University of Florida. He has been certified by the American Board of Health Physics since 1994 and licensed in Radiological Health Engineering by the Texas Board of Professional Engineers since 1992. In 2011, Dr. Bolch was elected Fellow of both the Health Physics Society and the American Association of Physicists in Medicine. He has been a member of the Society of Nuclear Medicine’s Medical Internal Radiation Dose (MIRD) Committee since 1993, a member of NCRP since 2005, and a member of Committee 2 of the International Commission on Radiological Protection (ICRP) since 2005. Within the latter, he serves as C2 Secretary and Leader of the ICRP Task Group on Computational Phantoms and Radiation Transport. He has published over 200 peer-reviewed journal articles, co-authored/edited 14 books/book chapters, and served as author on two NCRP reports, two ICRP publications, and two MIRD monographs.

Dr. Bolch has managed a broad research program including (1) National Institutes of Health (NIH) and U.S. Department of Energy funded projects to construct high-resolution models of the skeleton to support dose-response studies in radionuclide therapy and radiation epidemiology; (2) NIH funded projects to develop scalable NURBS-based and voxel-based computational phantoms of adult and pediatric patients and associated software for organ dose assessment in nuclear medicine, computed tomography, interventional fluoroscopy, and radiotherapy; (3) private company funded projects to develop stereotactic kilovoltage x-ray treatments for age-related macular degeneration and glaucoma; and (4) Centers for Disease Control and Prevention funded projects in stochastic modeling of worker inhalation and gamma-ray exposures following radiological accidents and potential terrorist events. He is the recipient of the 2014 Distinguish Scientific Achievement Award by the Health Physics Society acknowledging outstanding contributions to the science and technology of radiation safety.

became President of the NCRP in January 2019. She held the position of Executive Director and Chief Science Officer from 2016 to 2018. She was first elected to the Council in 2006 and served on the NCRP Board of Directors from 2008 to 2014. She was Vice President from 2011 to 2016 of Program Area Committee 1 on Basic Criteria, Epidemiology, Radiobiology, and Risk. She also served as Chair of the Program Committee for the 2011 Annual Meeting on “Scientific and Policy Challenges of Particle Radiations in Medical Therapy and Space Missions.” Dr. Held was a member of Scientific Committee (SC) 1-22 on Radiation Protection for Astronauts in Short-Term Missions and Phase I of SC 1-24 on Radiation Exposures in Space and the Potential of Central Nervous System Effects and an advisor to several NCRP committees.

Dr. Held is an Associate Radiation Biologist in the Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Associate Professor of Radiation Oncology (Radiation Biology) at Harvard Medical School (HMS). At MGH, Dr. Held leads a team that is involved in research on molecular mechanisms for the induction of bystander effects by high energy particles in cells and tissues, characterization of charged particle beam induced DNA damage responses and cell killing, development of a cancer screening platform for personalized radiation medicine, and mechanisms for regulation of DNA damage response by cell-cell communication. Dr. Held also teaches radiation biology to radiation oncology medical and physics residents and graduate students at MGH/HMS and the Massachusetts Institute of Technology.

Dr. Held earned her PhD in biology from the University of Texas, Austin. She has served on review panels for numerous federal agencies including the National Institutes of Health, the National Aeronautics and Space Administration (NASA), and the U.S. Army Medical Research and Material Command programs and other organizations such as the Radiological Society of North America. She is on the Editorial Boards of Radiation Research and the International Journal of Radiation Biology, and has served on committees for the National Academy of Science/National Research Council, NASA, and the American Society of Radiation Oncology. She is a past President of the Radiation Research Society.

is an Associate Attending Neuropsychologist in the Department of Psychiatry and Behavioral Sciences at Memorial Sloan-Kettering Cancer Center and an Associate Professor of Psychology in the Department of Psychiatry and the Department of Anesthesiology at Weill Cornell Medical College. His neuroimaging research focuses on the cognitive effects of cancer diagnosis and treatment, including surgery, anesthesia, chemotherapy, radiotherapy, and endocrine therapy, utilizing structural and functional techniques, as well as neurocognitive measures. His clinical expertise is in the assessment of cognitive abilities in adults following cancer treatment. He completed his postdoctoral training in clinical neuropsychology at Columbia University College of Physicians and Surgeons, a second fellowship in neuroimaging at Weill Cornell Medical College, and completed a predoctoral residency in neuropsychology at Yale University School of Medicine.

is President of Cascade Scientific, Inc., an environmental consulting firm. Dr. Grogan received her PhD from Imperial College of Science and Technology at the University of London in 1984 and has more than 25 y of experience in radioecology, environmental dose reconstruction, and the assessment of radioactive and nonradioactive hazardous wastes. She first worked at the Paul Scherrer Institute in Switzerland on the performance assessment of radioactive waste disposal for the Swiss National Cooperative for the Disposal of Radioactive Waste (Nagra). Dr. Grogan was actively involved in the early international cooperative efforts to test models designed to quantify the transfer and accumulation of radionuclides and other trace substances in the environment.

Validation of computer models developed to predict the fate and transport of radionuclides in the environment remains a key interest of hers. In 1989 Dr. Grogan returned to the United Kingdom as a senior consultant to Intera Information Technologies before moving to the United States a few years later, where she has worked closely with Risk Assessment Corporation managing the technical aspects of a wide variety of projects that tend to focus on public health risk from environmental exposure to chemicals and radionuclides. Dr. Grogan has served on committees for the National Academy of Sciences, the International Atomic Energy Agency, the U.S. Environment Protection Agency, and NCRP. She co-edited the text book Radiological Risk Assessment and Environmental Analysis published by Oxford University Press in July 2008, and authored the chapter on Model Validation.